The Alzheimer's disease neuroimaging initiative

Susanne G. Mueller, Michael W. Weiner, Leon J. Thal, Ronald Carl Petersen, Clifford R Jr. Jack, William Jagust, John Q. Trojanowski, Arthur W. Toga, Laurel Beckett

Research output: Contribution to journalArticle

483 Citations (Scopus)

Abstract

With increasing life expectancy in developed countries, the incidence of Alzheimer's disease (AD) and its socioeconomic impact are growing. Increasing knowledge of the mechanisms of AD facilitates the development of treatment strategies aimed at slowing down or preventing neuronal death. AD treatment trials using clinical outcome measures require long observation times and large patient samples. There is increasing evidence that neuroimaging and cerebrospinal fluid and blood biomarkers may provide information that may reduce sample sizes and observation periods. The Alzheimer's Disease Neuroimaging Initiative will help identify clinical, neuroimaging, and biomarker outcome measures that provide the highest power for measurement of longitudinal changes and for prediction of transitions.

Original languageEnglish (US)
Pages (from-to)869-877
Number of pages9
JournalNeuroimaging Clinics of North America
Volume15
Issue number4
DOIs
StatePublished - Nov 2005

Fingerprint

Neuroimaging
Alzheimer Disease
Biomarkers
Observation
Outcome Assessment (Health Care)
Life Expectancy
Developed Countries
Sample Size
Cerebrospinal Fluid
Clinical Trials
Incidence
Therapeutics

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Clinical Neurology
  • Radiological and Ultrasound Technology

Cite this

The Alzheimer's disease neuroimaging initiative. / Mueller, Susanne G.; Weiner, Michael W.; Thal, Leon J.; Petersen, Ronald Carl; Jack, Clifford R Jr.; Jagust, William; Trojanowski, John Q.; Toga, Arthur W.; Beckett, Laurel.

In: Neuroimaging Clinics of North America, Vol. 15, No. 4, 11.2005, p. 869-877.

Research output: Contribution to journalArticle

Mueller, SG, Weiner, MW, Thal, LJ, Petersen, RC, Jack, CRJ, Jagust, W, Trojanowski, JQ, Toga, AW & Beckett, L 2005, 'The Alzheimer's disease neuroimaging initiative', Neuroimaging Clinics of North America, vol. 15, no. 4, pp. 869-877. https://doi.org/10.1016/j.nic.2005.09.008
Mueller, Susanne G. ; Weiner, Michael W. ; Thal, Leon J. ; Petersen, Ronald Carl ; Jack, Clifford R Jr. ; Jagust, William ; Trojanowski, John Q. ; Toga, Arthur W. ; Beckett, Laurel. / The Alzheimer's disease neuroimaging initiative. In: Neuroimaging Clinics of North America. 2005 ; Vol. 15, No. 4. pp. 869-877.
@article{96c45cf0657c4021aa437554c8921cf5,
title = "The Alzheimer's disease neuroimaging initiative",
abstract = "With increasing life expectancy in developed countries, the incidence of Alzheimer's disease (AD) and its socioeconomic impact are growing. Increasing knowledge of the mechanisms of AD facilitates the development of treatment strategies aimed at slowing down or preventing neuronal death. AD treatment trials using clinical outcome measures require long observation times and large patient samples. There is increasing evidence that neuroimaging and cerebrospinal fluid and blood biomarkers may provide information that may reduce sample sizes and observation periods. The Alzheimer's Disease Neuroimaging Initiative will help identify clinical, neuroimaging, and biomarker outcome measures that provide the highest power for measurement of longitudinal changes and for prediction of transitions.",
author = "Mueller, {Susanne G.} and Weiner, {Michael W.} and Thal, {Leon J.} and Petersen, {Ronald Carl} and Jack, {Clifford R Jr.} and William Jagust and Trojanowski, {John Q.} and Toga, {Arthur W.} and Laurel Beckett",
year = "2005",
month = "11",
doi = "10.1016/j.nic.2005.09.008",
language = "English (US)",
volume = "15",
pages = "869--877",
journal = "Neuroimaging Clinics of North America",
issn = "1052-5149",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - The Alzheimer's disease neuroimaging initiative

AU - Mueller, Susanne G.

AU - Weiner, Michael W.

AU - Thal, Leon J.

AU - Petersen, Ronald Carl

AU - Jack, Clifford R Jr.

AU - Jagust, William

AU - Trojanowski, John Q.

AU - Toga, Arthur W.

AU - Beckett, Laurel

PY - 2005/11

Y1 - 2005/11

N2 - With increasing life expectancy in developed countries, the incidence of Alzheimer's disease (AD) and its socioeconomic impact are growing. Increasing knowledge of the mechanisms of AD facilitates the development of treatment strategies aimed at slowing down or preventing neuronal death. AD treatment trials using clinical outcome measures require long observation times and large patient samples. There is increasing evidence that neuroimaging and cerebrospinal fluid and blood biomarkers may provide information that may reduce sample sizes and observation periods. The Alzheimer's Disease Neuroimaging Initiative will help identify clinical, neuroimaging, and biomarker outcome measures that provide the highest power for measurement of longitudinal changes and for prediction of transitions.

AB - With increasing life expectancy in developed countries, the incidence of Alzheimer's disease (AD) and its socioeconomic impact are growing. Increasing knowledge of the mechanisms of AD facilitates the development of treatment strategies aimed at slowing down or preventing neuronal death. AD treatment trials using clinical outcome measures require long observation times and large patient samples. There is increasing evidence that neuroimaging and cerebrospinal fluid and blood biomarkers may provide information that may reduce sample sizes and observation periods. The Alzheimer's Disease Neuroimaging Initiative will help identify clinical, neuroimaging, and biomarker outcome measures that provide the highest power for measurement of longitudinal changes and for prediction of transitions.

UR - http://www.scopus.com/inward/record.url?scp=31544443575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31544443575&partnerID=8YFLogxK

U2 - 10.1016/j.nic.2005.09.008

DO - 10.1016/j.nic.2005.09.008

M3 - Article

C2 - 16443497

AN - SCOPUS:31544443575

VL - 15

SP - 869

EP - 877

JO - Neuroimaging Clinics of North America

JF - Neuroimaging Clinics of North America

SN - 1052-5149

IS - 4

ER -